This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In December 2024, the pharma industry reported 82 deals worth $5.2 billion, compared to the last 12-month (December 2023 to November 2024) average of 100 deals worth $16.8 These were the three major deals that contributed 70 per cent of the total deal value during December 2024. billion; AlpInvest Partners B.V.
Additionally, approval was recommended two genericmedicines: Enzalutamide Viatris (enzalutamide) to treat prostate cancer, and Nilotinib Accord (nilotinib) was also recommended to treat Philadelphia chromosome positive chronic myelogenous leukaemia.
The European Medicine Agency’s human medicines committee (CHMP) recommended marketing authorisations for the regulatory approval of three medicines at its January 2024 meeting last week. Additionally, a positive opinion for Niapelf (paliperidone), a genericmedicine for schizophrenia was adopted in the meeting.
The committee also recommended the biosimilar medicine Wezenla (ustekinumab) to treat of plaque psoriasis. Genericmedicine Eribulin Baxter (eribulin) was also granted a positive opinion by the committee, to treat breast cancer and liposarcoma. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.
At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. These products were designated as an orphan medicine during their development.
The post 9th Advanced GMP Workshop 2024 was organised by IPA appeared first on Express Pharma. It’s not just a goal; it is the foundation of our global leadership, and the trust placed in us.
These medicines were recommended by the CHMP to treat plaque psoriasis, paediatric plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn’s disease. The post CHMP meeting highlights – July 2024 appeared first on European Pharmaceutical Review. Tuznue (trastuzumab) for breast and gastric cancer.
percent between 2024 and 2031. Main drivers for the market were reported to be rising popularity of generics together with blockbuster and other small-molecule drugs going off-patent globally. Overall, increasing demand for genericmedicines will be a significant factor for growth. billion by 2031.
. “If accepted, these IP provisions will have drastic consequences on access to medicines and the health of patients in India and beyond. Millions of lives depend on India putting people’s health first and being able to continue supplying genericmedicines globally,” according to Dr Mantoo.
Early-bird registration for the India Annual Meeting is available through August 10, 2024. DIA is celebrating 60 years of bringing together leading minds to foster collaboration and advancement in global healthcare. To register or view the event programme click here.
Additionally, the Department of Pharmaceuticals, Government of India, directive requires strict compliance with the Uniform Code for Marketing Practices 2024. The ‘Pradhan Mantri Bhartiya Janaushadhi Pariyojana’ (9) promotes retail outlets to provide quality genericmedicines at affordable prices.
Additionally, the Department of Pharmaceuticals, Government of India, directive requires strict compliance with the Uniform Code for Marketing Practices 2024. The ‘Pradhan Mantri Bhartiya Janaushadhi Pariyojana’ (9) promotes retail outlets to provide quality genericmedicines at affordable prices.
Integrating ESG considerations into core pharma operations India, known as the “Pharmacy of the World,” produces over 20 per cent of the global supply of genericmedicines and plays a vital role in vaccine production, as per the Investindia.gov.in It meets the healthcare needs of over 1.4
josh.levin@usp.org Thu, 04/18/2024 - 12:57 USP Leadership In addition, they are more compact and 44% lighter than previous versions, on average. Changes include replacing previously used expanded polystyrene (EPS) thermoplastic foam components with 100% recycled fiber inserts. These USP documentary standards are recognized in U.S.
In response to this pervasive public health crisis and to maintain momentum toward action, USP and ACS CAN hosted a Congressional briefing in March 2024 to highlight the root causes, complexities, and pervasiveness of drug shortages, as well as the need for urgent and comprehensive solutions.
PharmaState.Academy organized a ‘Masterclass for International Pharmaceutical Marketing’ enthusiasts on January 28, 2024. He highlighted potential opportunities due to the low cost of skilled labor, expanding market size, and increasing global demand for generic drugs.
by the end of 2023 and may continue to rise in 2024 to 5%. Joy Polefrone, the executive director of the organization, says it aims to build a cluster of partners who are capable of manufacturing genericmedicines. JP Morgan predicts that the US unemployment rate could rise to 4.3%
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content